CDKN2A alterations and TP53 mutations are mutually exclusive events in the majority of ESFT cases, suggesting that either genetic insult is sufficient to inactivate the p53 pathway in these cancers [11, 48]. The gene discussed is CDKN2A; the disease is cancer.